Report ID: 10042906 |
Published Date: 21 Mar 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
HIV Vaccine Market Definition
Vaccines are made from very small and incubated amounts of weak or dead germs, such as viruses, or bacteria. Vaccines are used to build immunity against certain diseases. HIV or human immunodeficiency virus is the cause of AIDS, which is an incurable disease. HIV vaccines are being developed to combat the deadly disease, as there is no known cure for AIDS.
Global HIV Vaccine Market Report Scope
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~ 39% |
|
Base Year Market Size (2022) |
~ USD 351 Million |
|
Forecast Year Market Size (2033) |
~ USD 3 Billion |
|
Regional Scope |
|
Global HIV Vaccine Market Highlights Over 2023 - 2033
The global HIV vaccine market is estimated to garner a revenue of ~ USD 3 billion by the end of 2033 by growing at a CAGR of ~39% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~ USD 351 million in the year 2022. The primary factor leading to market growth is the global prevalence of human immunodeficiency virus (HIV) infections. According to the World Health Organization (WHO), since the beginning of the HIV epidemic, about 84.2 million people worldwide have been infected and about 40.1 million have lost their life.
GET A SAMPLE COPY OF THIS REPORT
WHO also estimates that globally there were 38.4 million HIV-positive cases at the end of 2021. It has been observed that most of the population suffering from HIV were in low- and middle-income countries. As of 2021, eastern and southern Africa had the highest percentage of people with HIV (~54%). In the same year western & central Africa, Asia & the Pacific, central & western Europe, and North America had ~14%, ~16%, and ~6% of HIV patients respectively.
Global HIV Vaccine Market: Growth Drivers and Challenges
Growth Drivers.
-
Access to HIV Treatment as a Crucial Step to Prevent Acquired Immunodeficiency Syndrome (AIDS) – It was estimated that, globally, about 76% comprising more than 28 million people with HIV, had access to antiretroviral therapy (ART) by the end of 2021. Further, in 2021, more than 80% of pregnant ladies with HIV were taking ART. This was to protect their health and prevent the transmission of HIV to babies during pregnancy and childbirth.
-
Broad Access to HIV Testing Making People Aware of Their Health – It was observed in 2021 that ~86% of the global population with HIV were aware of their HIV status.
-
Risk of Unprotected Sexual Intercourse, Prostitution, and Injecting Drugs – It was estimated in 2021 that more than 69% of the global population with HIV comprised of homosexual men, transgender people, and those who injected drugs and their sexual partners and sex workers and their clients.
-
High Investment for AIDS Response – By the end of 2021, it was estimated that more than USD 21 billion was available for response to AIDS only in low- and middle-income countries.
Challenges
-
Inadequate Adoption of Hiv Treatments in Different Parts of the World
-
Limiting Governmental Regulations on Vaccine Approvals
-
Virus Mutations Resulting in Drug Resistance
The global HIV vaccine market is segmented and analyzed for demand and supply by type into acute paronychia, Candidal paronychia, chronic paronychia, and pyogenic paronychia. Of these, chronic paronychia is anticipated to hold the largest market size by the end of 2033. One of the major factors leading to chronic paronychia in patients with HIV is the use of certain medications like Indinavir. For instance, it has been observed that more than 65% of patients who took Indinavir experienced its adverse effects.
Global HIV Vaccine Market Regional Synopsis
Regionally, the global HIV vaccine market is studied into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Amongst these markets, the market in the European region is projected to hold the largest market share by the end of 2033. The significant increase in HIV cases is the primary factor leading to the market growth in the region. It is estimated that there have been ~3 million diagnosed and reported cases of HIV in the WHO European Region during the last three decades. Additionally, up to 104770 people were newly diagnosed with HIV only in 2020.
Market Segmentation
Our in-depth analysis of the global HIV vaccine market includes the following segments:
|
By Type |
|
|
By Antibodies |
|
Customize this Report: Request Customization
Key Companies Dominating the Global HIV Vaccine Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global HIV vaccine market that are included in our report are AlphaVax, Inc., Argos Therapeutics, Inc., Bionor Holding AS, Celldex Therapeutics, Inc., GeneCure Biotechnologies, Genetic Immunity, Inc., GeoVax, GlaxoSmithKline plc, Inovio Pharmaceuticals, Inc., Sanofi-aventis Groupe, and others.
Global HIV Vaccine Market: Latest Developments
-
August 2020: GeoVax – announced the Phase 1 clinical trial initiation of a combination therapy utilizing MVA62B, its novel boost component to induce remission in patients with HIV.
-
March 2020: Celldex Therapeutics, Inc. – announced receiving a USD 1.7 million payment from Rockefeller University as a part of an existing agreement signed in 2013 regarding a collaboration in which the company manufactures and develops HIV antibodies for the university.
Key Reasons to Buy Our Report
-
The report covers a detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis, and challenges that impact market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessments for overall growth.
-
We provide customized reports as per the client's requirement helping them to see possible and unexpected challenges and unforeseen opportunities to help them reach their goal.
Frequently Asked Question
The market is segmented by type, antibodies, and by region.
Chronic paronychia is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10042906 |
Published Date: 21 Mar 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
